Incorporating spatial and single-cell data into therapeutic design will be essential for predicting which tumor regions—and which subclones—are likely to respond to PARP or ATR inhibition, and for identifying combination strategies that overcome spatially restricted immune escape. This evidence concerns the gene PARP1 and neoplasm.